Molecular Signatures of TMS Response in Treatment-Resistant Depression
NCT: NCT07039370 · RECRUITING
Brief Summary
Transcranial Magnetic Stimulation (TMS) therapy is an approved and effective treatment option for treatment-resistant depression (TRD). This study aims to identify biomarkers that predict TMS treatment response in TRD, provide insights into the neurobiological mechanisms underlying TMS efficacy, and contribute to personalized treatment strategies. By establishing proteomic and metabolomic signatures, this research seeks to enhance clinical decision-making, reduce healthcare costs, and improve patient outcomes in TRD. The findings will align with the precision medicine movement in psychiatry, advancing biomarker-driven therapeutic approaches for treatment-resistant depression.
Frequently Asked Questions
What is Molecular Signatures of TMS Response in Treatment-Resistant Depression?
Molecular Signatures of TMS Response in Treatment-Resistant Depression is a clinical trial registered under NCT07039370. Current status: RECRUITING.
What is the status of NCT07039370?
The current status of NCT07039370 (Molecular Signatures of TMS Response in Treatment-Resistant Depression) is: RECRUITING.
When did Molecular Signatures of TMS Response in Treatment-Resistant Depression start?
Molecular Signatures of TMS Response in Treatment-Resistant Depression started on 2025-06-15.
Official Source
View on ClinicalTrials.gov →Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.